Skip to content

Study · Systematic review · n = 49,602 · 2018

4 results

Glucagon-like peptide-1 receptor agonists and fracture risk: a network meta-analysis of randomized clinical trials.

Zhang YS, Weng WY, Xie BC, Meng Y, Hao YH, Liang YM, Zhou ZK

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA6 Aug 2018Cited by 75 (Europe PMC)

PMID30083774 (opens in a new tab)DOI10.1007/s00198-018-4649-8 (opens in a new tab)PepBankPUB-30083774
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In a network meta-analysis of trials in type 2 diabetes, liraglutide ranked third, after exenatide and dulaglutide, for probability of being the safest option for fracture risk.

    In plain wordsIn pooled trials in type 2 diabetes, liraglutide ranked behind exenatide and dulaglutide for lowest fracture risk.

    Peptide
    Liraglutide
    Outcome
    Not applicableFracture risk ranking
    Study

    n = 49,602

    Comparator
    Placebo and other GLP-1 RAs
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Ranking probability
    1.39%
    liraglutide

    Source sentences

    Summary
    Exenatide had the highest probability to be the safest option with regard to the risk of fracture (0.07 ‰), followed by dulaglutide (1.04%), liraglutide (1.39%), albiglutide (5.61%), lixisenatide (8.07%), and semaglutide (18.72%).
    1 context sentence
    Summary · context
    There were 54 eligible random control trials (RCTs) with 49,602 participants, including 28,353 patients treated with GLP-1 RAs.
  2. 02HumanSystematic reviewEfficacy outcome

    In a network meta-analysis of trials in type 2 diabetes, semaglutide ranked last of the six listed GLP-1 RAs for probability of being the safest option for fracture risk.

    In plain wordsIn pooled trials in type 2 diabetes, semaglutide ranked behind five other GLP-1 drugs for lowest fracture risk.

    Peptide
    Semaglutide
    Outcome
    Not applicableFracture risk ranking
    Study

    n = 49,602

    Comparator
    Placebo and other GLP-1 RAs
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Ranking probability
    18.72%
    semaglutide

    Source sentences

    Summary
    Exenatide had the highest probability to be the safest option with regard to the risk of fracture (0.07 ‰), followed by dulaglutide (1.04%), liraglutide (1.39%), albiglutide (5.61%), lixisenatide (8.07%), and semaglutide (18.72%).
    1 context sentence
    Summary · context
    There were 54 eligible random control trials (RCTs) with 49,602 participants, including 28,353 patients treated with GLP-1 RAs.

Studies that did not test the peptide alone2

In this study, the peptide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking the peptide.

  1. 03HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including liraglutide) were associated with a decreased risk of bone fracture.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group, including liraglutide, were linked to a lower fracture risk.

    Peptide
    Liraglutide
    Outcome
    DecreaseFracture risk, pooled GLP-1 RAs
    Study

    n = 49,602

    Comparator
    Placebo or other anti-hyperglycemic drugs
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    GLP-1 RAs were associated with a decreased bone fracture risk
    1 context sentence
    Summary · context
    There were 54 eligible random control trials (RCTs) with 49,602 participants, including 28,353 patients treated with GLP-1 RAs.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 04HumanNot a test of Semaglutide aloneSystematic reviewEfficacy outcome

    In adults with type 2 diabetes, pooled GLP-1 receptor agonists (including semaglutide) were associated with a decreased risk of bone fracture.

    In plain wordsIn adults with type 2 diabetes, GLP-1 drugs as a group, including semaglutide, were linked to a lower fracture risk.

    Peptide
    Semaglutide
    Outcome
    DecreaseFracture risk, pooled GLP-1 RAs
    Study

    n = 49,602

    Comparator
    Placebo or other anti-hyperglycemic drugs
    Outcome group
    Bone and joint · Musculoskeletal

    Source sentences

    Summary
    GLP-1 RAs were associated with a decreased bone fracture risk
    1 context sentence
    Summary · context
    There were 54 eligible random control trials (RCTs) with 49,602 participants, including 28,353 patients treated with GLP-1 RAs.

    In this study, Semaglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Semaglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 4 to 5Current

    27 Oct 2026, 16:36 UTC

    The same notice was added 2 times, first on 21 Oct 2026, 18:59 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  2. Version 3

    12 Oct 2026, 12:10 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.